POLE

Across TCGA pan-cancer cohorts, POLE Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated POLE data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher POLE Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLE expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

KIRC, ACC, and UCEC are the cancer types where POLE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.085	0.806	<.001	36	view →
ACC	DFS	Median	All	0.067	0.674	<.001	36	view →
UCEC	DFS	Median	All	0.759	0.619	<.001	36	view →
KIRP	OS	Median	All	0.267	0.904	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
ESCA	DFS	Median	All	0.261	0.551	.001	12	view →
BLCA	DFS	Median	All	0.707	0.317	.020	8	view →
PCPG	DFS	Median	All	0.088	0.768	.002	6	view →
CESC	DFS	Median	II,III,IV	0.407	0.713	.042	6	view →
LIHC	OS	Median	All	0.015	0.784	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LGG	DFS	Median	All	0.276	0.731	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

POLE–KIRC (OS)

Open the KIRC breakdown →